Nonalcoholic Fatty Liver Clinical Trial
Official title:
Weight, Energy, Lipids, and the Liver (WELL) Study: Dietary Fat Quality and Ectopic Lipids in the Liver
The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy metabolism in participants who consume 3 study foods per day for 16 week, while maintaining their body weight.
The study objectives include: 1. To determine the impact of dietary soybean oil on ectopic liver fat and visceral adipose in adults with nonalcoholic fatty liver disease (NAFLD) or similar diagnosis 2. To evaluate the effect of soybean oil supplementation on postprandial lipids, markers of inflammation and energy metabolism 3. To measure the strength of the association of change in plasma linoleic acid with changes in ectopic liver fat, visceral adipose, and postprandial lipids, markers of inflammation and energy metabolism 4. To explore emerging mechanistic targets of LA-rich soybean oils that are linked with reduced liver fat and better cardiometabolic health ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04031729 -
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03725631 -
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD
|
N/A | |
Active, not recruiting |
NCT05084404 -
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT05081427 -
Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
|
||
Recruiting |
NCT05430178 -
Metabolic Pathology of Pediatric NAFLD
|
N/A | |
Recruiting |
NCT04389593 -
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference
|
||
Active, not recruiting |
NCT03696797 -
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
|
N/A | |
Terminated |
NCT02365233 -
Fatty Liver Study in Patients With Type II Diabetes
|
Phase 4 | |
Completed |
NCT05309642 -
Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study
|
N/A | |
Completed |
NCT03763877 -
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
|
Phase 2 | |
Completed |
NCT04828551 -
Noninvasive Biomarkers of Metabolic Liver Disease 1.1
|
N/A | |
Completed |
NCT05792423 -
Conditionally Increased Output (CIO) Enhanced Ultrasound System
|
N/A | |
Not yet recruiting |
NCT06335771 -
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
|
N/A | |
Recruiting |
NCT02815891 -
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
|
||
Not yet recruiting |
NCT05908877 -
Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
|
||
Not yet recruiting |
NCT04887766 -
Study on GS300 on NAFLD
|
N/A | |
Completed |
NCT03986684 -
Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
|
||
Recruiting |
NCT05165706 -
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
|
N/A | |
Completed |
NCT04235205 -
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT05680233 -
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
|
Phase 1 |